Education
About Us
Working with TipRanks
Follow Us
Viewray (VRAYQ)
OTHER OTC:VRAYQ
VRAYQ Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $4.96
Previous CloseN/A
Volume41.00
Average Volume (3M)N/A
Market Cap
$183.00
Enterprise ValueN/A
Total Cash (Recent Filing)$81.29M
Total Debt (Recent Filing)$85.13M
Price to Earnings (P/E)―
Beta118.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding183,402,040
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VRAYQ FAQ
What was Viewray’s price range in the past 12 months?
Viewray lowest stock price was <$0.01 and its highest was $4.96 in the past 12 months.
What is Viewray’s market cap?
Viewray’s market cap is $183.00.
When is Viewray’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Viewray’s earnings last quarter?
Currently, no data Available
Is Viewray overvalued?
According to Wall Street analysts Viewray’s price is currently Overvalued.
Does Viewray pay dividends?
Viewray does not currently pay dividends.
What is Viewray’s EPS estimate?
Viewray’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viewray have?
Viewray has 183,402,040 shares outstanding.
What happened to Viewray’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Viewray?
Currently, no hedge funds are holding shares in VRAYQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viewray
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
EKSO BIONICS
―
Enveric Biosciences
―
NLS Pharmaceutics
―
GRI Bio
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
5.94% Mutual Funds
<0.01% Other Institutional Investors
94.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---